Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ202 plus dexamethasone in relapsed or refractory multiple myeloma (single-arm phase II, China)
CTR20192344Phase 2Completed
- Sponsor
- I-Mab
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of felzartamab in multiple myeloma (MM), sponsored by I-Mab. Started Nov 2019; status: completed.
02
Drugs
felzartamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20192344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192344.